Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

164 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A comprehensive analysis of the COL29A1 gene does not support a role in eczema.
Naumann A, Söderhäll C, Fölster-Holst R, Baurecht H, Harde V, Müller-Wehling K, Rodríguez E, Ruether A, Franke A, Wagenpfeil S, Novak N, Mempel M, Kalali BN, Allgaeuer M, Koch J, Gerhard M, Melén E, Wahlgren CF, Kull I, Stahl C, Pershagen G, Lauener R, Riedler J, Doekes G, Scheynius A, Illig T, von Mutius E, Schreiber S, Kere J, Kabesch M, Weidinger S. Naumann A, et al. J Allergy Clin Immunol. 2011 May;127(5):1187-94.e7. doi: 10.1016/j.jaci.2010.12.1123. Epub 2011 Feb 25. J Allergy Clin Immunol. 2011. PMID: 21353297
Predictive value of food sensitization and filaggrin mutations in children with eczema.
Filipiak-Pittroff B, Schnopp C, Berdel D, Naumann A, Sedlmeier S, Onken A, Rodriguez E, Fölster-Holst R, Baurecht H, Ollert M, Ring J, Cramer C, von Berg A, Bauer CP, Herbarth O, Lehmann I, Schaaf B, Koletzko S, Wichmann HE, Heinrich J, Weidinger S; GINIplus and LISAplus study groups. Filipiak-Pittroff B, et al. Among authors: naumann a. J Allergy Clin Immunol. 2011 Dec;128(6):1235-1241.e5. doi: 10.1016/j.jaci.2011.09.014. Epub 2011 Oct 26. J Allergy Clin Immunol. 2011. PMID: 22030464
Uric acid as a novel biomarker for bone-marrow function and incipient hematopoietic reconstitution after aplasia in patients with hematologic malignancies.
Haen SP, Eyb V, Mirza N, Naumann A, Peter A, Löffler MW, Faul C, Vogel W, Bethge WA, Rammensee HG, Kanz L, Heni M. Haen SP, et al. Among authors: naumann a. J Cancer Res Clin Oncol. 2017 May;143(5):759-771. doi: 10.1007/s00432-017-2348-z. Epub 2017 Feb 16. J Cancer Res Clin Oncol. 2017. PMID: 28210842
Retrospective single center analysis of outcome, risk factors and therapy in steroid refractory graft-versus-host disease after allogeneic hematopoietic cell transplantation.
Axt L, Naumann A, Toennies J, Haen SP, Vogel W, Schneidawind D, Wirths S, Moehle R, Faul C, Kanz L, Axt S, Bethge WA. Axt L, et al. Among authors: naumann a. Bone Marrow Transplant. 2019 Nov;54(11):1805-1814. doi: 10.1038/s41409-019-0544-y. Epub 2019 May 14. Bone Marrow Transplant. 2019. PMID: 31089279 Clinical Trial.
Risankizumab for Ulcerative Colitis: Two Randomized Clinical Trials.
Louis E, Schreiber S, Panaccione R, Bossuyt P, Biedermann L, Colombel JF, Parkes G, Peyrin-Biroulet L, D'Haens G, Hisamatsu T, Siegmund B, Wu K, Boland BS, Melmed GY, Armuzzi A, Levine P, Kalabic J, Chen S, Cheng L, Shu L, Duan WR, Pivorunas V, Sanchez Gonzalez Y, D'Cunha R, Neimark E, Wallace K, Atreya R, Ferrante M, Loftus EV Jr; INSPIRE and COMMAND Study Group. Louis E, et al. JAMA. 2024 Sep 17;332(11):881-897. doi: 10.1001/jama.2024.12414. JAMA. 2024. PMID: 39037800 Clinical Trial.
Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's Disease.
Peyrin-Biroulet L, Chapman JC, Colombel JF, Caprioli F, D'Haens G, Ferrante M, Schreiber S, Atreya R, Danese S, Lindsay JO, Bossuyt P, Siegmund B, Irving PM, Panaccione R, Cao Q, Neimark E, Wallace K, Anschutz T, Kligys K, Duan WR, Pivorunas V, Huang X, Berg S, Shu L, Dubinsky M; SEQUENCE Study Group. Peyrin-Biroulet L, et al. N Engl J Med. 2024 Jul 18;391(3):213-223. doi: 10.1056/NEJMoa2314585. N Engl J Med. 2024. PMID: 39018531 Clinical Trial.
164 results